ThalassaX Therapeutics United States Ltd today announced that the first patient has been successfully dosed in the U.S. Phase I clinical trial of CS231295, a next-generation brain-penetrant Aurora B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results